Table 2 Changes of miRNA expression in BJAB, OCI-LY3 and SU-DHL-6 cells after incubation with the c-MYC-inhibitor (5 µM), LY294002 (5 µM), Rapamycin (500 nM), PD98059 (10 µM) and SB203580 (10 µM) for 24 h

BJAB cells

c-MYC-inh.

ΔΔCT

1.78 ± 0.13 ↓

0.16 ± 0.11

0.80 ± 0.14 ↓

−0.89 ± 0.14 ↑

−1.68 ± 0.17 ↑

−0.12 ± 0.14

Fold of untreated

0.29 (0.27–0.32)*

0.90 (0.83–0.97)

0.57 (0.54–0.61)*

1.85 (1.68–2.04)*

3.20 (2.85–3.61)*

1.09 (0.99–1.20)

LY294002

ΔΔCT

1.06 ± 0.18 ↓

0.21 ± 0.19

1.02 ± 0.20 ↓

0.52 ± 0.12 ↑

−0.54 ± 0.09 ↑

0.06 ± 0.11

Fold of untreated

0.48 (0.42–0.54)*

0.86 (0.76–0.99)

0.49 (0.43–0.57)*

1.43 (1.32–1.56)*

1.45 (1.37–1.55)*

0.96 (0.89–1.04)

Rapamycin

ΔΔCT

1.28 ± 0.08 ↓

0.27 ± 0.24

−0.64 ± 0.15 ↑

−0.86 ± 0.12 ↑

−0.53 ± 0.11 ↑

0.21 ± 0.20

Fold of untreated

0.41 (0.39–0.44)*

0.83 (0.70–0.98)

1.56 (1.40–1.73)*

1.82 (1.67–1.97)*

1.44 (1.34–1.56)*

0.86 (0.75–0.99)

PD98059

ΔΔCT

0.03 ± 0.08

−0.04 ± 0.07

−0.65 ± 0.12 ↑

−0.60 ± 0.15 ↑

−1.51 ± 0.14 ↑

0.05 ± 0.10

Fold of untreated

0.98 (0.93–1.04)

1.03 (0.98–1.08)

1.57 (1.44–1.71)*

1.52 (1.37–1.68)*

2.85 (2.58–3.14)*

0.97 (0.90–1.04)

SB203580

ΔΔCT

−0.04 ± 0.13

−0.01 ± 0.11

0.03 ± 0.07

−0.01 ± 0.07

−0.05 ± 0.12

0.06 ± 0.09

Fold of untreated

1.03 (0.94–1.13)

1.01 (0.93–1.09)

0.98 (0.93–1.03)

1.01 (0.96–1.06)

1.04 (0.95–1.13)

0.96 (0.90–1.02)

OCI-LY3 cells

c-MYC-inh.

ΔΔCT

1.20 ± 0.15 ↓

0.19 ± 0.17

0.83 ± 0.12 ↓

−0.70 ± 0.13 ↑

−1.47 ± 0.16 ↑

−0.06 ± 0.11

Fold of untreated

0.44 (0.39–0.48)*

0.88 (0.78–0.99)

0.56 (0.52–0.61)*

1.62 (1.48–1.78)*

2.77 (2.48–3.10)*

1.04 (0.97–1.13)

LY294002

ΔΔCT

0.76 ± 0.14 ↓

0.05 ± 0.09

0.61 ± 0.14 ↓

−0.77 ± 0.13 ↑

−0.84 ± 0.18 ↑

0.13 ± 0.12

Fold of untreated

0.59 (0.54–0.65)*

0.97 (0.91–1.03)

0.66 (0.59–0.72)*

1.71 (1.56–1.87)*

1.79 (1.58–2.03)*

0.91 (0.84–0.99)

Rapamycin

ΔΔCT

1.45 ± 0.17 ↓

0.20 ± 0.18

−0.80 ± 0.16 ↑

−0.60 ± 0.10 ↑

−0.93 ± 0.12 ↑

−0.02 ± 0.06

Fold of untreated

0.37 (0.33–0.41)*

0.87 (0.77–0.99)

1.74 (1.56–1.95)*

1.52 (1.40–1.64)*

1.91 (1.75–2.07)*

1.01 (0.97–1.06)

PD98059

ΔΔCT

−0.04 ± 0.08

0.26 ± 0.15

−0.77 ± 0.13 ↑

−0.53 ± 0.13 ↑

0.06 ± 0.10

−0.14 ± 0.16

Fold of untreated

1.03 (0.97–1.09)

0.90 (0.81–0.99)

1.71 (1.56–1.87)*

1.44 (1.32–1.58)*

0.96 (0.90–1.03)

1.10 (0.99–1.23)

SB203580

ΔΔCT

0.05 ± 0.08

−0.05 ± 0.07

−0.17 ± 0.15

0.09 ± 0.13

0.00 ± 0.09

−0.14 ± 0.13

Fold of untreated

0.97 (0.91–1.02)

1.04 (0.99–1.09)

0.89 (0.80–0.99)

0.94 (0.86–1.03)

1.00 (0.94–1.06)

1.10 (1.01–1.21)

SU-DHL-6 cells

c-MYC-inh.

ΔΔCT

0.68 ± 0.13 ↓

−0.03 ± 0.07

ne

−0.99 ± 0.17 ↑

0.08 ± 0.11

ne

Fold of untreated

0.62 (0.57–0.68)*

1.02 (0.97–1.07)

1.99 (1.77–2.23)*

0.95 (0.81–1.02)

LY294002

ΔΔCT

0.12 ± 0.20

−0.21 ± 0.24

ne

0.73 ± 0.10 ↓

−0.03 ± 0.13

ne

Fold of untreated

0.92 (0.80–1.06)

1.16 (0.98–1.37)

0.60 (0.56–0.65)*

1.02 (0.93–1.12)

Rapamycin

ΔΔCT

1.14 ± 0.14 ↓

0.05 ± 0.07

ne

−0.77 ± 0.13 ↑

−0.07 ± 0.11

ne

Fold of untreated

0.45 (0.41–0.50)*

0.97 (0.92–1.01)

1.71 (1.56–1.87)*

1.05 (0.97–1.13)

PD98059

ΔΔCT

−0.08 ± 0.14

0.06 ± 0.07

ne

−0.07 ± 0.11

−0.01 ± 0.06

ne

Fold of untreated

1.06 (0.96–1.16)

0.96 (0.91–1.01)

1.05 (0.97–1.13)

1.01 (0.97–1.05)

SB203580

ΔΔCT

−0.10 ± 0.09

−0.06 ± 0.10

ne

0.08 ± 0.08

0.03 ± 0.12

ne

Fold of untreated

1.07 (1.01–1.14)

1.04 (0.97–1.12)

0.95 (0.90–1.00)

0.98 (0.90–1.06)